HomeBiotechBIO-TECHNE TO PRESENT AT THE MORGAN STANLEY 20th ANNUAL GLOBAL HEALTHCARE CONFERENCE

BIO-TECHNE TO PRESENT AT THE MORGAN STANLEY 20th ANNUAL GLOBAL HEALTHCARE CONFERENCE

Published on

Disclaimer

 

PR Newswire



MINNEAPOLIS


,


Aug. 30, 2022


/PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH) today announced that

Jim Hippel

, Executive Vice President and Chief Financial Officer, will present at the Morgan Stanley 20

th

Annual Global Healthcare Conference on

Tuesday, September 13, 2022

, at

1:30 p.m. EST

. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne’s Investor Relations website at

https://investors.bio-techne.com/ir-calendar

.


Bio-Techne Corporation

(NASDAQ: TECH) is a leading developer and manufacturer of high-quality purified proteins and reagent solutions – notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, T-Cell activation and gene editing technologies. Bio-Techne’s product portfolio also includes protein analysis solutions, sold under the ProteinSimple brand name, offering researchers efficient and streamlined options for automated Western blot and multiplexed ELISA workflow. These reagent and protein analysis solutions are sold to biomedical researchers as well as clinical research laboratories and constitute the Protein Sciences Segment. Bio-Techne also develops and manufactures diagnostic products including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and custom assay development on dedicated clinical instruments. Bio-Techne’s genomic tools include advanced tissue-based

in situ

hybridization assays (ISH) for research and clinical use, sold under the ACD brand as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx

®

Prostate test for prostate cancer diagnosis. These diagnostic and genomic products comprise Bio-Techne’s Diagnostics and Genomics Segment. Bio-Techne products are integral components of scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately

$1.1 billion

in net sales in fiscal 2022 and has approximately 3,000 employees worldwide.


Contact:


David Clair, Vice President, Investor Relations



[email protected]


612-656-4416

Cision
View original content to download multimedia:

https://www.prnewswire.com/news-releases/bio-techne-to-present-at-the-morgan-stanley-20th-annual-global-healthcare-conference-301612990.html

SOURCE Bio-Techne Corporation

rt BIO-TECHNE TO PRESENT AT THE MORGAN STANLEY 20th ANNUAL GLOBAL HEALTHCARE CONFERENCE

Latest News

REGENXBIO Presents Additional Positive Interim Data from the Phase I/II/III CAMPSIITE(TM) Trial of RGX-121 for the Treatment of MPS II (Hunter Syndrome) at the...

Disclaimer   PR Newswire - New data in Cohort 3 using pivotal program dose level demonstrates largest median...

Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2022

Disclaimer Additional one-year data continue to show rapid and sustained normalization to healthy levels...

Real-World Administrative Claims Analysis Demonstrates That Almost Half of Migraine Patients Discontinue Barbiturate Use After Initiation of Nurtec ODT

Disclaimer   PR Newswire Results from this study demonstrate a robust and clinically meaningful reduction in...

FDA Grants Orphan Drug Designation for BioCryst’s ALK-2 Inhibitor, BCX9250, for the Treatment of Fibrodysplasia Ossificans Progressiva

Disclaimer RESEARCH TRIANGLE PARK, N.C., Aug. 31, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced...

More like this

Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium

Disclaimer SAN DIEGO, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today...

BioCryst Presents Data Demonstrating >99 Percent Suppression of Alternative Pathway Complement Activity with BCX9930 in C3G Patients

Disclaimer Study represents first data with BCX9930 in C3G patients RESEARCH TRIANGLE PARK, N.C., Aug. 26,...

Iovance Biotherapeutics Initiates Biologics License Application (BLA) Submission for Lifileucel in Advanced Melanoma

Disclaimer First TIL Therapy BLA Submission Initiated with U.S. Food and Drug Administration Complete BLA Submission...

ChemoCentryx Announces TAVNEOS® (avacopan) Presentations at Upcoming Medical Conferences

Disclaimer SAN CARLOS, Calif., Aug. 24, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today...

CANCER Publishes Study Demonstrating Substantial Disease Burden for Patients with Systemic Mastocytosis

Disclaimer   PR Newswire -- Patients across the spectrum of disease reported substantial symptom burden, as well...